Terns Pharmaceuticals, Inc. stock is up 91.19% since 30 days ago. The next earnings date is Mar 25, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 December’s closed higher than November. 100% of analysts rate it a buy.
Terns Pharmaceuticals, Inc. develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.